Abstract
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions, and data on its usage in saphenous vein graft interventions are limited. This retrospective, observational study evaluated the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients who underwent saphenous vein graft intervention with distal protection devices. We found that bivalirudin use is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anticoagulants / adverse effects
-
Anticoagulants / therapeutic use*
-
Antithrombins
-
Coronary Artery Disease / surgery*
-
Female
-
Heparin / therapeutic use*
-
Hirudins / adverse effects
-
Humans
-
Male
-
Middle Aged
-
Peptide Fragments / adverse effects
-
Peptide Fragments / therapeutic use*
-
Postoperative Complications / prevention & control*
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use*
-
Retrospective Studies
-
Saphenous Vein / transplantation*
-
Stents
-
Thrombosis / prevention & control*
-
Treatment Outcome
Substances
-
Anticoagulants
-
Antithrombins
-
Hirudins
-
Peptide Fragments
-
Recombinant Proteins
-
Heparin
-
bivalirudin